[go: up one dir, main page]

SG11201805835WA - Modified oncolytic virus - Google Patents

Modified oncolytic virus

Info

Publication number
SG11201805835WA
SG11201805835WA SG11201805835WA SG11201805835WA SG11201805835WA SG 11201805835W A SG11201805835W A SG 11201805835WA SG 11201805835W A SG11201805835W A SG 11201805835WA SG 11201805835W A SG11201805835W A SG 11201805835WA SG 11201805835W A SG11201805835W A SG 11201805835WA
Authority
SG
Singapore
Prior art keywords
international
january
english
pct
unless
Prior art date
Application number
SG11201805835WA
Inventor
Robert Coffin
Original Assignee
Replimune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57796748&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201805835W(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1600381.6A external-priority patent/GB201600381D0/en
Priority claimed from GBGB1600380.8A external-priority patent/GB201600380D0/en
Priority claimed from GBGB1600382.4A external-priority patent/GB201600382D0/en
Application filed by Replimune Ltd filed Critical Replimune Ltd
Publication of SG11201805835WA publication Critical patent/SG11201805835WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16633—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11 M1111101110101011111 HO 11111011101 01111111101100IM III International Bureau ... .... ..Yjd (10) International Publication Number (43) International Publication Date ..... .....!;, 13 July 2017 (13.07.2017) WI P0 I P CT WO 2017/118864 Al (51) International Patent Classification: C12N 7/00 (2006.01) AO, BZ, DO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: PCT/GB2017/050036 HN, KP, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (22) International Filing Date: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, 9 January 2017 (09.01.2017) NI, RU, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (25) Filing Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (26) Publication Language: English ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 1600380.8 8 January 2016 (08.01.2016) GB 1600381.6 8 January 2016 (08.01.2016) GB 1600382.4 8 January 2016 (08.01.2016) GB kind GM, TZ, of regional protection available): ARIPO (BW, GH, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: REPLIMUNE LIMITED [GB/GB]; 69 In- novation Centre, Milton Park, Oxford Oxfordshire OX14 4RQ (GB). DK, LV, SM, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (72) Inventor: COFFIN, Robert; c/o Replimune Limited, 69 GW, KM, ML, MR, NE, SN, TD, TG). Innovation Drive, Milton Park, Abingdon Oxfordshire Published: OX14 4RQ (GB). — with international search report (Art. 21(3)) = (74) Agent: TUXWORTH, Pamela Mary; J A Kemp & Co, 14 South Square, Gray's Inn, London Greater London WC1R 5JJ with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the = — = (GB). description (Rules 13bis.4(d)(i) and 48.2 (a)(viii)) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (81) _ with sequence listing part of description (Rule 5.2(a)) = = = = = = = = = Il 7r ,tD GO GO 1-1 1-1 IN 1-1 0 \" (54) Title: MODIFIED ONCOLYTIC VIURS C ) ,..,.. (57) : The present invention relates to an oncolytic virus comprising: (i) a fusogenic protein-encoding gene; and (ii) an im- mune stimulatory molecule-encoding gene.
SG11201805835WA 2016-01-08 2017-01-09 Modified oncolytic virus SG11201805835WA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1600381.6A GB201600381D0 (en) 2016-01-08 2016-01-08 Virus strain
GBGB1600380.8A GB201600380D0 (en) 2016-01-08 2016-01-08 Modified virus
GBGB1600382.4A GB201600382D0 (en) 2016-01-08 2016-01-08 Engineered virus
PCT/GB2017/050036 WO2017118864A1 (en) 2016-01-08 2017-01-09 Modified oncolytic viurs

Publications (1)

Publication Number Publication Date
SG11201805835WA true SG11201805835WA (en) 2018-08-30

Family

ID=57796748

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201805835WA SG11201805835WA (en) 2016-01-08 2017-01-09 Modified oncolytic virus
SG10202108724YA SG10202108724YA (en) 2016-01-08 2017-01-09 Modified oncolytic virus

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202108724YA SG10202108724YA (en) 2016-01-08 2017-01-09 Modified oncolytic virus

Country Status (13)

Country Link
US (13) US10626377B2 (en)
EP (8) EP3778881A1 (en)
JP (8) JP6959258B2 (en)
KR (2) KR20250026348A (en)
CN (3) CN109153977B (en)
AU (2) AU2017205216B2 (en)
CA (3) CA3010987A1 (en)
DK (4) DK3400291T4 (en)
ES (4) ES2831080T5 (en)
IL (2) IL260480B (en)
MX (1) MX2018008413A (en)
SG (2) SG11201805835WA (en)
WO (4) WO2017118865A1 (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2695101A (en) * 2000-01-21 2001-07-31 Biovex Ltd Virus strains
TWI531652B (en) 2005-12-02 2016-05-01 美國紐約大學西奈山醫學院 Chimeric viruses presenting non-native surface proteins and uses thereof
WO2008153832A2 (en) 2007-05-31 2008-12-18 Krishnan Ramu Switched reluctance machines with minimum stator core
NZ711946A (en) 2013-03-14 2020-05-29 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
NZ739503A (en) 2015-07-16 2023-06-30 Bioxcel Therapeutics Inc A novel approach for treatment of cancer using immunomodulation
CA3010987A1 (en) 2016-01-08 2017-07-13 Replimune Limited Oncolytic herpes simplex virus type 1 strain
BR112018015390A2 (en) 2016-01-27 2018-12-18 Oncorus, Inc. oncolytic viral vectors and uses thereof
RS65430B1 (en) 2016-03-16 2024-05-31 Amal Therapeutics Sa Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine
EP3380621A4 (en) * 2016-04-22 2019-05-08 Immvira Co., Limited REQUIRED VECTOR CONSTRUCTION OF ONCOLYTIC HERPES SIMPLEX VIRUSES (OHSV) AND CONSTRUCTS FOR THE TREATMENT OF CANCER
TWI808055B (en) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-1 inhibitors
TWI794171B (en) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-l1 inhibitors
US10888594B2 (en) 2016-05-30 2021-01-12 National University Corporation Tottori University Genetically engineered vaccinia viruses
US20190336552A1 (en) 2016-05-30 2019-11-07 Astellas Pharma Inc. Genetically engineered vaccinia viruses
WO2018006005A1 (en) 2016-06-30 2018-01-04 Oncorus, Inc. Pseudotyped oncolytic viral delivery of therapeutic polypeptides
KR102879364B1 (en) 2016-09-21 2025-11-04 아말 테라퓨틱스 에스에이 A novel complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for treatment of colorectal cancer
CN108261426B (en) * 2017-01-04 2019-04-05 杭州康万达医药科技有限公司 Pharmaceutical composition and its application in the drug for the treatment of tumour and/or cancer
GB201700350D0 (en) * 2017-01-09 2017-02-22 Replimune Ltd Altered virus
KR20190139225A (en) 2017-04-28 2019-12-17 머크 샤프 앤드 돔 코포레이션 Biomarkers for Cancer Treatment
JOP20190256A1 (en) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
WO2019023483A1 (en) 2017-07-26 2019-01-31 Oncorus, Inc. Oncolytic viral vectors and uses thereof
TN2020000015A1 (en) 2017-08-03 2021-10-04 Amgen Inc Interleukin-21 muteins and methods of treatment
EP4403175A3 (en) 2017-09-08 2024-10-02 Amgen Inc. Inhibitors of kras g12c and methods of using the same
CN109554353B (en) * 2017-09-26 2021-08-06 杭州康万达医药科技有限公司 Isolated recombinant oncolytic poxvirus, pharmaceutical compositions and use thereof in a medicament for the treatment of tumors and/or cancers
EP3708657A4 (en) * 2017-11-08 2021-08-25 Kagoshima University ONCOLYTIC VIRUS (ONCOLYTIC IMMUNOTHERAPY) CAPABLE OF EFFECTIVELY TREATING EVEN METASTATIC CANCER WHILE ENSURING SAFETY, THROUGH AN EXPRESSION REGULATION SYSTEM PROVIDING OPTIMAL LEVEL OF EXPRESSION OF AN IMMUNOGENIC GENE
BR112020009363A2 (en) * 2017-11-13 2020-10-27 Bioxcel Therapeutics, Inc. methods and compositions to treat cancer by modifying multiple arms of the immune system
US11865081B2 (en) 2017-12-29 2024-01-09 Virogin Biotech Canada Ltd. Oncolytic viral delivery of therapeutic polypeptides
SG11202005605SA (en) 2018-01-12 2020-07-29 Amgen Inc Anti-pd-1 antibodies and methods of treatment
WO2019147982A1 (en) * 2018-01-26 2019-08-01 Celldex Therapeutics, Inc. Methods of treating cancer with dendritic cell mobilizing agents
GB201804473D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy Modified oncolytic adenoviruses
CN108635380A (en) * 2018-04-13 2018-10-12 北京唯源立康生物科技有限公司 Recombination oncolytic virus composition and its application in preparing the drug for treating tumour
JP2021527694A (en) * 2018-06-21 2021-10-14 レプリミュン リミテッド Treatment with oncolytic virus
AU2019292580A1 (en) * 2018-06-29 2021-02-04 Krystal Biotech, Inc. Compositions and methods for antibody delivery
CN109161561A (en) * 2018-08-09 2019-01-08 湖北科技学院 A kind of the novel oncolytic virus and its construction method of selectively killing prostate gland cancer cell
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
WO2020052551A1 (en) * 2018-09-10 2020-03-19 Genesail Biotech (Shanghai) Co. Ltd. A modified oncolytic virus, composition and use thereof
US11638730B2 (en) * 2018-09-26 2023-05-02 Astellas Pharma Inc. Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy
AR117547A1 (en) 2018-12-27 2021-08-11 Amgen Inc LYOPHILIZED VIRUS FORMULATIONS
CN111606999B (en) * 2019-02-26 2022-09-06 南京惟亚德生物医药有限公司 Replicative oncolytic adenovirus with functions of activating immune co-stimulatory signaling pathway and blocking immune checkpoint and application thereof
AU2020232264A1 (en) * 2019-03-05 2021-08-26 Amgen Inc. Use of oncolytic viruses for the treatment of cancer
TW202102543A (en) 2019-03-29 2021-01-16 美商安進公司 Use of oncolytic viruses in the neoadjuvant therapy of cancer
CN110054678B (en) * 2019-05-16 2023-04-18 中国医学科学院血液病医院（血液学研究所） Membrane-bound mFLT3LG protein and application thereof
CN110218707B (en) * 2019-05-29 2021-10-22 上海市公共卫生临床中心 Novel oncolytic virus and preparation method and application thereof
WO2021024897A1 (en) * 2019-08-05 2021-02-11 国立大学法人東海国立大学機構 Combination drug for treating malignant tumor, pharmaceutical composition for treating malignant tumor, and pharmaceutical composition for malignant tumor treatment
AU2020378088A1 (en) * 2019-11-06 2022-05-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Replication-enhanced oncolytic adenoviruses
CN110982795B (en) * 2020-03-05 2020-06-16 北京唯源立康生物科技有限公司 Herpes simplex virus and application thereof
CN110982794B (en) * 2020-03-05 2020-06-16 北京唯源立康生物科技有限公司 Modified herpes simplex virus
EP4112724A4 (en) * 2020-03-05 2023-08-23 Beijing Wellgene Biotech Co., Ltd. Herpes simplex virus and use thereof
JPWO2021193081A1 (en) * 2020-03-23 2021-09-30
EP4172323A1 (en) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
US11839659B2 (en) 2020-07-02 2023-12-12 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
CN112941039A (en) * 2021-02-01 2021-06-11 南京大学 Novel vesicular oncolytic virus and application thereof in preparation of antitumor drugs
DE102022104146A1 (en) 2021-03-19 2022-09-22 Yamada Manufacturing Co., Ltd. STEERING DEVICE
AU2022255538A1 (en) * 2021-04-08 2023-09-28 Immvira Biopharmaceuticals Co., Limited Genetically modified oncolytic herpes simplex virus delivering chemokine and tumor associated/specific antigen
WO2022245808A1 (en) * 2021-05-18 2022-11-24 The Penn State Research Foundation Oncolytic virus based cancer therapy
CN113583979B (en) * 2021-08-03 2022-11-22 杭州荣谷生物科技有限公司 Recombinant oncolytic vaccinia virus, preparation method and application thereof
EP4464441A4 (en) 2022-01-11 2025-12-03 Mitsubishi Materials Corp SURFACE-COATED CUTTING TOOL
WO2024055022A2 (en) * 2022-09-08 2024-03-14 Virogin Biotech Canada Ltd Oncolytic virus expressing an immune cell engager for tumor targeting
WO2025248110A1 (en) * 2024-05-31 2025-12-04 Replimune Limited An oncolytic herpes simplex virus (hsv) and an anti-pd-1 antibody for use in treating braf mutant melanoma

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594014B2 (en) 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
CA1282721C (en) 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
DE3584341D1 (en) 1984-08-24 1991-11-14 Upjohn Co RECOMBINANT DNA COMPOUNDS AND EXPRESSION OF POLYPEPTIDES LIKE TPA.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5698531A (en) 1989-03-31 1997-12-16 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5328688A (en) 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
US6770274B1 (en) 1990-09-14 2004-08-03 The General Hospital Corporation Viral mutant HSV mediated destruction of neoplastic cells
US6040169A (en) 1991-01-31 2000-03-21 Medical Research Council Herpes simplex virus-1 deletion variants and vaccines thereof
JP3974167B2 (en) 1992-03-31 2007-09-12 アーチ デベロプメント コーポレイション Methods and compositions for treating genes, tumors and viral infections, and preventing programmed cell death (apoptosis)
US6699468B1 (en) 1994-06-23 2004-03-02 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
CA2234060A1 (en) 1995-10-06 1997-04-10 Arch Development Corporation Methods and compositions for viral enhancement of cell killing
US5824318A (en) 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
GB9700411D0 (en) 1997-01-10 1997-02-26 Univ London Eukaryotic gene expression cassette and uses thereof
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
US6428968B1 (en) 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
CA2388807C (en) 1999-11-12 2013-08-06 Matthew C. Coffey Viruses for the treatment of cellular proliferative disorders
AU2695101A (en) 2000-01-21 2001-07-31 Biovex Ltd Virus strains
EP1381280B1 (en) 2001-03-27 2011-05-11 Catherex, Inc. Viral vectors and their use in therapeutic methods
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
WO2006002394A2 (en) 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
EP1819735A1 (en) 2004-11-04 2007-08-22 Pfizer Products Inc. Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer
US9866961B2 (en) 2004-12-01 2018-01-09 Todd Beauchamp Multi-channel loudspeaker enclosure with laterally projecting wings and method for orienting and driving multiple loudspeakers
KR100996801B1 (en) 2005-03-08 2010-11-25 파마시아 앤드 업존 캄파니 엘엘씨 Anti-MADCAA Antibody Compositions
PT2650020T (en) 2005-05-06 2016-12-12 Providence Health & Services - Oregon Trimeric ox40-immunoglobulin fusion protein and methods of use
EP1909849B1 (en) 2005-06-23 2013-08-07 The University Of Houston Use of mutant herpes simplex virus-2 for cancer therapy
GB0522476D0 (en) 2005-11-03 2005-12-14 Biovex Ltd Oncolytic herpes virus vectors
AU2007241023B2 (en) 2006-03-30 2013-11-28 University Of California Methods and compositions for localized secretion of anti-CTLA-4 antibodies
US8313896B2 (en) * 2008-04-04 2012-11-20 The General Hospital Corporation Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
EP2307033A4 (en) 2008-05-29 2012-06-13 Gen Hospital Corp USE OF ONCOLYTIC HERPIC VIRUSES FOR KILLING CANCER STEM CELLS
BRPI0920679A2 (en) 2008-10-08 2022-05-17 Intrexon Corp Cells constructed expressing multiple immunomodulators and uses thereof
US20100297072A1 (en) 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
CA2781300A1 (en) 2009-11-20 2011-05-26 Infinity Pharmaceuticals, Inc. Methods and compositions for treating hedgehog-associated cancers
WO2011119925A2 (en) * 2010-03-25 2011-09-29 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses for treatment of cancers
WO2011118866A1 (en) 2010-03-26 2011-09-29 연세대학교 산학협력단 Method for evaluation request using network
CN103221544A (en) * 2010-09-24 2013-07-24 昂克斯治疗有限公司 Oncolytic adenoviral vectors coding for monoclonal anti-CTLA-4 antibodies
HRP20182194T1 (en) * 2011-09-08 2019-02-22 New York University ONCOLYTIC HERPES SIMPLEX VIRUS AND ITS THERAPEUTIC USE
FI20115914L (en) 2011-09-16 2013-03-17 Oncos Therapeutics Ltd MODIFIED ONCOLYTIC VIRUS
DK2806883T3 (en) * 2012-01-25 2019-07-22 Dnatrix Inc BIOMARKERS AND COMBINATION THERAPIES WITH USING ONCOLYTIC VIRUS AND IMMUNOMODULATION
US20150190505A1 (en) 2012-07-30 2015-07-09 Alex Wah Hin Yeung Live and in-vivo tumor specific cancer vaccine system developed by co-administration of either at least two or all three of the following components such as tumor cells, an oncolytic virus vector with transgenic expression of gm-csf and an immune checkpoint modulator
ES2871910T3 (en) 2012-08-30 2021-11-02 Amgen Inc A method of treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor
WO2014066532A1 (en) 2012-10-23 2014-05-01 Bristol-Myers Squibb Company Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
HK1211235A1 (en) 2013-02-22 2016-05-20 霍夫曼-拉罗奇有限公司 Methods of treating cancer and preventing drug resistance
NZ711946A (en) 2013-03-14 2020-05-29 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
EA039404B1 (en) 2013-09-03 2022-01-24 Медиммун Лимитед Attenuated newcastle disease virus (ndv) of a 73t strain for treating neoplasia, method of selectively killing tumor cells and method of inducing tumor regression using same
EP3831398A1 (en) 2013-10-25 2021-06-09 PsiOxus Therapeutics Limited Oncolytic adenoviruses armed with heterologous genes
JP6588024B2 (en) 2013-10-28 2019-10-09 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション Oncolytic HSV vector
CA2931322A1 (en) 2013-11-22 2015-05-28 Dnatrix, Inc. Adenovirus expressing immune cell stimulatory receptor agonist(s)
WO2015128313A1 (en) 2014-02-25 2015-09-03 Deutsches Krebsforschungszentrum Rna viruses for immunovirotherapy
MA39818A (en) * 2014-03-30 2017-02-08 Benevir Biopharm Inc Exogenous tap inhibitor "armed" oncolytic viruses and therapeutic uses thereof
EP3169340B1 (en) 2014-07-16 2020-09-02 Institut Gustave Roussy Combination of oncolytic virus with immune checkpoint modulators
EP3552615B8 (en) 2014-07-16 2022-03-02 Transgene Oncolytic virus for expression of immune checkpoint modulators
US20160040186A1 (en) 2014-08-07 2016-02-11 Xiaoyun Liu Dna construct and method for transgene expression
GB201419579D0 (en) 2014-11-03 2014-12-17 Iomet Pharma Ltd Pharmaceutical compound
CA2974529C (en) 2015-01-23 2023-08-15 Dreamwell, Ltd. Automated mattress manufacturing process and apparatus
CA3010987A1 (en) * 2016-01-08 2017-07-13 Replimune Limited Oncolytic herpes simplex virus type 1 strain
EP3380621A4 (en) 2016-04-22 2019-05-08 Immvira Co., Limited REQUIRED VECTOR CONSTRUCTION OF ONCOLYTIC HERPES SIMPLEX VIRUSES (OHSV) AND CONSTRUCTS FOR THE TREATMENT OF CANCER
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
US12029647B2 (en) * 2017-03-07 2024-07-09 4C Medical Technologies, Inc. Systems, methods and devices for prosthetic heart valve with single valve leaflet
JP2021527694A (en) 2018-06-21 2021-10-14 レプリミュン リミテッド Treatment with oncolytic virus
AU2019410148A1 (en) 2018-12-21 2021-08-12 Ottawa Hospital Research Institute Modified orthopoxvirus vectors

Also Published As

Publication number Publication date
JP7038065B2 (en) 2022-03-17
MX2018008413A (en) 2019-02-20
US12458696B2 (en) 2025-11-04
CA3010987A1 (en) 2017-07-13
AU2022279486B2 (en) 2025-07-31
SG10202108724YA (en) 2021-09-29
CA3011004A1 (en) 2017-07-13
US12465639B2 (en) 2025-11-11
US20250352646A1 (en) 2025-11-20
EP4219696A2 (en) 2023-08-02
ES2831080T5 (en) 2023-10-30
US10612005B2 (en) 2020-04-07
DK3400291T3 (en) 2020-11-30
DK3400293T3 (en) 2020-10-19
CN109415703A (en) 2019-03-01
WO2017118865A1 (en) 2017-07-13
US20210254019A1 (en) 2021-08-19
EP3400293A1 (en) 2018-11-14
HK1257074A1 (en) 2019-10-11
ES2841300T3 (en) 2021-07-08
ES3041885T3 (en) 2025-11-17
IL282985A (en) 2021-06-30
EP3400293B2 (en) 2023-07-12
JP2023113885A (en) 2023-08-16
EP3805376A1 (en) 2021-04-14
JP2022078225A (en) 2022-05-24
IL282985B (en) 2022-04-01
EP3400291B2 (en) 2024-02-28
EP3400290A1 (en) 2018-11-14
US20230212531A1 (en) 2023-07-06
US20230203453A1 (en) 2023-06-29
JP7038664B2 (en) 2022-03-18
ES2943150T3 (en) 2023-06-09
CN109312309B (en) 2024-04-02
US20200199542A1 (en) 2020-06-25
EP4628577A2 (en) 2025-10-08
WO2017118867A1 (en) 2017-07-13
AU2017205216B2 (en) 2022-11-24
EP3400291A1 (en) 2018-11-14
US20240301365A1 (en) 2024-09-12
KR20180103956A (en) 2018-09-19
US12024724B2 (en) 2024-07-02
JP2019501671A (en) 2019-01-24
KR102762431B1 (en) 2025-02-03
KR20250026348A (en) 2025-02-25
EP3400291B1 (en) 2020-11-04
AU2017205216A1 (en) 2018-08-09
CN109153977B (en) 2022-11-01
JP2025163138A (en) 2025-10-28
US11427810B2 (en) 2022-08-30
IL260480B (en) 2021-05-31
EP3805376B1 (en) 2025-08-06
AU2022279486A1 (en) 2023-02-02
JP7295192B2 (en) 2023-06-20
DK3400293T4 (en) 2023-08-28
US20190032024A1 (en) 2019-01-31
US10947513B2 (en) 2021-03-16
JP2022002531A (en) 2022-01-11
EP3400292A1 (en) 2018-11-14
DK3400290T5 (en) 2024-09-23
HK1257224A1 (en) 2019-10-18
CA3011009A1 (en) 2017-07-13
US10626377B2 (en) 2020-04-21
WO2017118864A1 (en) 2017-07-13
US12397053B2 (en) 2025-08-26
US20190040366A1 (en) 2019-02-07
US20200208122A1 (en) 2020-07-02
EP3400290B1 (en) 2023-04-05
US20230130992A1 (en) 2023-04-27
JP6959258B2 (en) 2021-11-02
DK3400290T3 (en) 2023-05-01
ES2831080T3 (en) 2021-06-07
HK1257480A1 (en) 2019-10-18
BR112018013930A2 (en) 2018-12-11
JP2019501670A (en) 2019-01-24
JP2024153748A (en) 2024-10-29
DK3805376T3 (en) 2025-09-29
US12049647B2 (en) 2024-07-30
US20190022157A1 (en) 2019-01-24
EP3778881A1 (en) 2021-02-17
JP2019500909A (en) 2019-01-17
CN109153977A (en) 2019-01-04
DK3400291T4 (en) 2024-04-02
US11473063B2 (en) 2022-10-18
CN109312309A (en) 2019-02-05
US10570377B2 (en) 2020-02-25
US20190015466A1 (en) 2019-01-17
WO2017118866A1 (en) 2017-07-13
US20240018488A1 (en) 2024-01-18
ES2841300T5 (en) 2024-08-06
EP3400292B1 (en) 2020-08-26
CN109415703B (en) 2024-08-30
EP3400293B1 (en) 2020-09-16
EP4219696A3 (en) 2023-09-27

Similar Documents

Publication Publication Date Title
SG11201805835WA (en) Modified oncolytic virus
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201807195VA (en) Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
SG11201909432SA (en) Compounds for increasing genome editing efficiency
SG11201811048UA (en) Single-cell transcript sequencing
SG11201804161VA (en) Compositions comprising bacterial strains
SG11201810003UA (en) Using programmable dna binding proteins to enhance targeted genome modification
SG11202000312UA (en) Encapsulated polynucleotides and methods of use
SG11201804934PA (en) Novel Compounds
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201900021PA (en) Methods and compositions for the treatment of cancer
SG11201805001UA (en) Method of treating influenza a
SG11201811446SA (en) Process for recovering viral products using functionalised chromatography media
SG11201908472VA (en) Compositions and methods for activating nk cells
SG11201903411YA (en) Anti-p53 antibodies
SG11201903833VA (en) Tray system for transfer, counting, storage and disposal of surgical instruments
SG11201805191SA (en) Yeast cell
SG11201810940XA (en) Methods of treating pancreatic cancer
SG11201906383WA (en) A layered medical data computer architecture
SG11201809406PA (en) Construct and vector for intragenic plant transformation
SG11201909837YA (en) Methods for treating lung disorders
SG11201811763SA (en) B-cell-mimetic cells
SG11201906359SA (en) Compositions and methods for maturation of oocytes in vitro